Key terms

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ALNY news

Apr 09 10:25am ET Buy Rating Affirmed for Alnylam Pharma on Strong Zilebesiran Trial Results and Lucrative Roche Partnership Apr 09 7:15am ET Alnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic Partnerships Apr 08 10:50pm ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO) Apr 08 8:25am ET Jefferies Keeps Their Buy Rating on Alnylam Pharma (ALNY) Apr 08 6:40am ET Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), ALX Oncology Holdings (ALXO) Apr 08 5:51am ET Alnylam Pharma (ALNY) Gets a Hold from J.P. Morgan Apr 07 8:19am ET Alnylam Pharmaceuticals presents results from KARDIA-2 Phase 2 study Apr 05 8:50am ET Analysts Conflicted on These Healthcare Names: Teladoc (TDOC) and Alnylam Pharma (ALNY) Mar 28 7:10am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Mar 25 6:55am ET Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS Pipeline Mar 07 7:20am ET Analysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR) Mar 06 7:40am ET Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT) Mar 06 7:25am ET Buy Rating Affirmed for Alnylam Pharma as Zilebesiran Shows Blockbuster Potential Mar 06 6:10am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE) Mar 05 10:15am ET Buy Rating Affirmed for Alnylam Pharma Amid Positive Clinical Trials and Strategic Collaborations Mar 05 8:33am ET Roche, Alnylam report KARDIA-2 study met primary endpoint Mar 05 7:47am ET Alnylam reports KARDIA-2 zilebesiran study met primary endpoint of lower SBP Mar 04 4:43pm ET Alnylam Pharmaceuticals Finalizes Exit Deal with EVP Franchini Feb 23 5:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and Bausch Health Companies (BHC) Feb 21 7:31am ET Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Teladoc (TDOC) and Alnylam Pharma (ALNY) Feb 20 8:50am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 20 7:31am ET Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT) Feb 18 11:55pm ET Maintaining Hold on Alnylam Pharmaceuticals Amid Clinical and Financial Uncertainties Feb 17 1:00am ET Alnylam Pharmaceuticals’ New Regulation Risk – A Cause for Worry? Feb 16 7:58am ET Alnylam price target lowered to $161 from $171 at Wells Fargo Feb 16 7:57am ET Oppenheimer Remains a Hold on Alnylam Pharma (ALNY) Feb 16 7:50am ET Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Moderna (MRNA) and Alnylam Pharma (ALNY) Feb 16 7:43am ET Alnylam price target lowered to $225 from $250 at Chardan Feb 16 7:37am ET Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY) Feb 16 7:30am ET Strategic Trial Adjustments Bolster Alnylam Pharma’s Buy Rating and Anticipate Share Value Surge Feb 16 7:27am ET Alnylam price target lowered to $283 from $284 at Canaccord

No recent news articles are available for ALNY

ALNY Financials

1-year income & revenue

Key terms

ALNY Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ALNY Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms